drugset / Trial / NCT04707508

Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

NCT04707508

Phase 4 Completed 203 enrolled Nantou Christian Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder in which a substantial number of patients cannot attain treatment target despite antidiabetic drugs. The renin-angiotensin system (RAS) has recently been implicated in the development of insulin resistance and impaired glucose metabolism. This study investigates the effect of adding RAS inhibitors to standard antidiabetic therapy in patients with T2DM. The primary outcome measure is the change in serum glycosylated hemoglobin A1c after 24 weeks of treatment. Secondary outcomes measures include changes in plasma lipid profile and blood pressure after treatment.

Timeline

Start
2017-12-01
Primary completion
2019-01-23
Completion
2019-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 80 mg
Comparator Metformin Small molecule